Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Margaret Macro"'
Autor:
Shaji Kumar, Maria Delioukina, Torben Plesner, Noopur Raje, Jessica Vermeulen, Hartmut Goldschmidt, Supratik Basu, Hang Quach, Rian Van Rampelbergh, Saad Z. Usmani, Xavier Leleu, Aurore Perrot, Thierry Facon, Jianping Wang, Tahamtan Ahmadi, Michael O'Dwyer, Clarissa M. Uhlar, Katja Weisel, Cyrille Hulin, Robert Z. Orlowski, Brenda Tromp, Philippe Moreau, Christopher P. Venner, Joseph R. Mace, Mourad Tiab, Margaret Macro, Laurent Frenzel, Hareth Nahi, Nizar J. Bahlis
Publikováno v:
Facon, T, Kumar, S K, Plesner, T, Orlowski, R Z, Moreau, P, Bahlis, N, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M, Perrot, A, Venner, C P, Weisel, K, Mace, J R, Raje, N, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Ahmadi, T, Wang, J, Van Rampelbergh, R, Uhlar, C M, Tromp, B, Delioukina, M, Vermeulen, J & Usmani, S Z 2021, ' Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA) : overall survival results from a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 22, no. 11, pp. 1582-1596 . https://doi.org/10.1016/S1470-2045(21)00466-6
Background: In the primary analysis of the phase 3 MAIA trial (median follow-up 28·0 months), a significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethas
Autor:
Kastritis E., Palladini G., Minnema M. C., Wechalekar A. D., Jaccard A., Lee H. C., Sanchorawala V., Gibbs S., Mollee P., Venner C. P., Lu J., Schonland S., Gatt M. E., Suzuki K., Kim K., Cibeira M. T., Beksac M., Libby E., Valent J., Hungria V., Wong S. W., Rosenzweig M., Bumma N., Huart A., Dimopoulos M. A., Bhutani D., Waxman A. J., Goodman S. A., Zonder J. A., Lam S., Song K., Hansen T., Manier S., Roeloffzen W., Jamroziak K., Kwok F., Shimazaki C., Kim J. -S., Crusoe E., Ahmadi T., Tran N., Qin X., Vasey S. Y., Tromp B., Schecter J. M., Weiss B. M., Zhuang S. H., Vermeulen J., Merlini G., Comenzo R. L., Bradley Augustson, Fiona Kwok, Peter Mollee, Simon Gibbs, Chantal Doyen, Greet Bries, Isabelle Vande Broek, Ka Lung Wu, Koen Theunissen, Koen Van Eygen, Michel Delforge, Nathalie Meuleman, Philip Vlummens, Angelo Maiolino, Breno Moreno de Gusmão, Carlos Eduardo Miguel, Edvan Crusoe, Fernanda Moura, Fernanda Seguro, Jandey Bigonha, Juliane Musacchio, Karla Zanella, Laura Garcia, Marcelo Eduardo Zanella Capra, Reijane Alves de Assis, Rosane Bittencourt, Vania Hungria, Walter Braga, Wolney Barreto, Christopher Venner, Donna Reece, Emilie Lemieux-Blanchard, Kevin Song, Michael Sebag, Selay Lam, Victor Zepeda, Haitao Zhang, Jianda Hu, Jin Lu, Juan Li, Songfu Jiang, Ting Niu, Wenming Chen, Xiaonong Chen, Zhen Cai, Zhou Fude, Maja Oelholm Vase, Morten Salomo, Niels Abildgaard, Alain Fuzibet, Anne-Marie Stoppa, Arnaud Jaccard, Bertrand Arnulf, Bruno Moulin, Bruno Royer, David Ghez, Denis Caillot, Dominique Chauveau, Franck Bridoux, Lauriane Clement-Filliatre, Lionel Karlin, Lotfi Benboubker, Mamoun Dib, Margaret Macro, Mohamad Mohty, Olivier Decaux, Olivier Hermine, Olivier Tournilhac, Philippe Moreau, Salomon Manier, Sylvain Choquet, Véronique Dorvaux, Alexander Carpinteiro, Axel Nogai, Britta Besemer, Christoph Roellig, Roland Fenk, Stefan Knop, Stefan Schönland, Timon Hansen, Argiris Symeonidis, Efstathios Kastritis, Gabor Mikala, Tamás Masszi, Zsolt Nagy, Celia Suriu, Hila Magen, Iuliana Vaxman, Lev Shvidel, Meir Preis, Moshe Gatt, Noa Lavi, Osnat Jarchowsky, Tamar Tadmor, Yael Cohen, Angelo Vacca, Giovanni Palladini, Mario Boccadoro, Maurizio Martelli, Maurizio Musso, Michele Cavo, Chihiro Shimazaki, Hiroyuki Takamatsu, Kazutaka Sunami, Kenshi Suzuki, Nagaaki Katoh, Shinsuke Iida, Takayuki Ikezoe, Tomoaki Fujisaki, Yuta Katayama, Chang Ki Min, Ho-Jin Shin, Jin Seok Kim, Jung Yong Hong, Ki Hyun Kim, Sung-Soo Yoon, Aline Ramirez, Alvaro Cabrera, Christian Ramos, David Gomez Almaguer, Deborah Martinez, Guillermo Ruiz, Helen Dayani Caballero, Juan Antonio Flores Jimenez, Annemiek Broijl, Laurens Nieuwenhuizen, Monique Minnema, Paula Ypma, Wilfried Roeloffzen, Dominik Dytfeld, Grzegorz Charlinski, Grzegorz Helbig, Krzysztof Jamroziak, Sebastian Grosicki, Wieslaw Jedrzejczak, Albert Oriol Rocafiguera, Elham Askari, Fernando Escalante Barrigon, Isabel Krsnik Castello, Javier De la Rubia Comos, Jesus Martin Sanchez, Joaquin Martinez Lopez, Jose Angel Hernandez Rivas, Luis Felipe Casado Montero, Maria Jesus Blanchard Rodriguez, Maria Teresa Cibeira Lopez, Maria Victoria Mateos Manteca, Marta Sonia Gonzalez Perez, Mercedes Gironella Mesa, Rafael Rios Tamayo, Ramon Lecumberri Villamediana, Ricarda Garcia Sanchez, Sunil Lakhwani, Yolanda Gonzalez, Hareth Nahi, Kristina Carlsson, Markus Hansson, Ulf-Henrik Mellqvist, Ali Unal, Burhan Ferhanoglu, Hayri Ozsan, Levent Undar, Mehmet Turgut, Mehmet Yilmaz, Meral Beksac, Muhlis Cem Ar, Muzaffer Demir, Sevgi Besisik, Ashutosh Wechalekar, Jamie Cavenagh, Jim Cavet, Mark Cook, Rachel Hall, Adam Waxman, Anuj Mahindra, Cesar Rodriguez Valdes, Christine Ye, Craig Reeder, Daphne Friedman, David Siegel, Divaya Bhutani, Edward Libby, Eva Medvedova, Frank Passero, Giada Bianchi, Giampaolo Talamo, Guido Tricot, Hans Lee, Heather Landau, Jan Moreb, Jason Valent, Jeffrey Matous, Jeffrey A Zonder, Jesus Berdeja, Jonathan Kaufman, Keith Stockerl-Goldstein, Keren Osman, Ketan Doshi, Kevin Barton, Larry Anderson, Manisha Bhutani, Mehmet Kocoglu, Michael Rosenzweig, Michael Schuster, Michaela Liedtke, Morie Gertz, Naresh Bumma, Natalie Callander, Raymond Comenzo, Robert Vescio, Roger Pearse, Sandy W Wong, Stacey A Goodman, Stefano Tarantolo, Taimur Sher, Tibor Kovacsovics, Tomer Mark, Vaishali Sanchorawala, William Bensinger
Publikováno v:
New England Journal of Medicine, 385(1), 46-58. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 385 (1), pp.46-58. ⟨10.1056/NEJMoa2028631⟩
Kastritis, E, Palladini, G, Minnema, M C, Wechalekar, A D, Jaccard, A, Lee, H C, Sanchorawala, V, Gibbs, S, Mollee, P, Venner, C P, Lu, J, Schönland, S, Gatt, M E, Suzuki, K, Kim, K, Cibeira, M T, Beksac, M, Libby, E, Valent, J, Hungria, V, Wong, S W, Rosenzweig, M, Bumma, N, Huart, A, Dimopoulos, M A, Bhutani, D, Waxman, A J, Goodman, S A, Zonder, J A, Lam, S, Song, K, Hansen, T, Manier, S, Roeloffzen, W, Jamroziak, K, Kwok, F, Shimazaki, C, Kim, J-S, Crusoe, E, Ahmadi, T, Tran, N, Qin, X, Vasey, S Y, Tromp, B, Schecter, J M, Weiss, B M, Zhuang, S H, Vermeulen, J, Merlini, G, for the ANDROMEDA Trial Investigators & Abildgaard, N 2021, ' Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis ', The New England Journal of Medicine, vol. 385, no. 1, pp. 46-58 . https://doi.org/10.1056/NEJMoa2028631
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 385 (1), pp.46-58. ⟨10.1056/NEJMoa2028631⟩
Kastritis, E, Palladini, G, Minnema, M C, Wechalekar, A D, Jaccard, A, Lee, H C, Sanchorawala, V, Gibbs, S, Mollee, P, Venner, C P, Lu, J, Schönland, S, Gatt, M E, Suzuki, K, Kim, K, Cibeira, M T, Beksac, M, Libby, E, Valent, J, Hungria, V, Wong, S W, Rosenzweig, M, Bumma, N, Huart, A, Dimopoulos, M A, Bhutani, D, Waxman, A J, Goodman, S A, Zonder, J A, Lam, S, Song, K, Hansen, T, Manier, S, Roeloffzen, W, Jamroziak, K, Kwok, F, Shimazaki, C, Kim, J-S, Crusoe, E, Ahmadi, T, Tran, N, Qin, X, Vasey, S Y, Tromp, B, Schecter, J M, Weiss, B M, Zhuang, S H, Vermeulen, J, Merlini, G, for the ANDROMEDA Trial Investigators & Abildgaard, N 2021, ' Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis ', The New England Journal of Medicine, vol. 385, no. 1, pp. 46-58 . https://doi.org/10.1056/NEJMoa2028631
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease.We rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b685c6c0877c79c6650b72aaec2ee26
https://research.rug.nl/en/publications/74938df3-de87-47e6-b870-977d2f5bae19
https://research.rug.nl/en/publications/74938df3-de87-47e6-b870-977d2f5bae19
Autor:
Bertrand Arnulf, Aurore Perrot, Bruno Royer, Laurent Frenzel, David Lavergne, Frank Bridoux, Sylvie Chevret, Fabien Le Bras, Cyrille Touzeau, Giampaolo Merlini, Véronique Dorvaux, Murielle Roussel, Eileen M Boyle, Anne-Marie Stoppa, Margaret Macro, Arnaud Jaccard, Lionel Karlin, Giovanni Palladini, Antoine Huart, Pierre Morel
Publikováno v:
Blood. 135:1531-1540
Daratumumab is a human monoclonal antibody targeting CD38, an antigen uniformly expressed by plasma cells in multiple myeloma and light-chain amyloidosis (AL). We report the results of a prospective multicenter phase 2 study of daratumumab monotherap
Autor:
Matthijs Westerman, Bertrand Arnulf, Frédérique Kuhnowski, Tahamtan Ahmadi, Annemiek Broijl, Lotfi Benboubker, Marie-Christiane Vekemans, Sonja Zweegman, Xavier Leleu, Maria Krevvata, Cyrille Touzeau, Veronique Vanquickelberghe, Hélène Caillon, Denis Caillot, Ke Zhang, Soraya Wuilleme, Pieter Sonneveld, Michel Delforge, Mark-David Levin, Jean-Richard Eveillard, Jill Corre, Aurore Perrot, Philippe Moreau, Mohamad Mohty, Nathalie Meuleman, Anne-Marie Stoppa, Jessica Vermeulen, Kon-Siong Jie, Saskia K. Klein, Tobias Kampfenkel, Fritz Offner, Thierry Facon, Hervé Avet-Loiseau, Chantal Doyen, Frédérique Orsini-Piocelle, Cécile Sonntag, Murielle Roussel, Carla de Boer, Jean-Pierre Marolleau, Reda Garidi, Thomas Dejoie, Mourad Tiab, Cyrille Hulin, Lionel Karlin, Margaret Macro, Jean Fontan, Sanjay Vara, Jérôme J. Lambert, Niels W.C.J. van de Donk, Marie C. Béné, Martine Escoffre-Barbe, Karim Belhadj
Publikováno v:
The Lancet Oncology, 22(10), 1378-1390. Lancet Publishing Group
Moreau, P, Hulin, C, Perrot, A, Arnulf, B, Belhadj, K, Benboubker, L, Béné, M C, Zweegman, S, Caillon, H, Caillot, D, Corre, J, Delforge, M, Dejoie, T, Doyen, C, Facon, T, Sonntag, C, Fontan, J, Mohty, M, Jie, K S, Karlin, L, Kuhnowski, F, Lambert, J, Leleu, X, Macro, M, Orsini-Piocelle, F, Roussel, M, Stoppa, A M, van de Donk, N W C J, Wuillème, S, Broijl, A, Touzeau, C, Tiab, M, Marolleau, J P, Meuleman, N, Vekemans, M C, Westerman, M, Klein, S K, Levin, M D, Offner, F, Escoffre-Barbe, M, Eveillard, J R, Garidi, R, Ahmadi, T, Krevvata, M, Zhang, K, de Boer, C, Vara, S, Kampfenkel, T, Vanquickelberghe, V, Vermeulen, J, Avet-Loiseau, H & Sonneveld, P 2021, ' Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 10, pp. 1378-1390 . https://doi.org/10.1016/S1470-2045(21)00428-9
The Lancet. Oncology, Vol. 22, no. 10, p. 1378-1390 (2021)
Moreau, P, Hulin, C, Perrot, A, Arnulf, B, Belhadj, K, Benboubker, L, Béné, M C, Zweegman, S, Caillon, H, Caillot, D, Corre, J, Delforge, M, Dejoie, T, Doyen, C, Facon, T, Sonntag, C, Fontan, J, Mohty, M, Jie, K S, Karlin, L, Kuhnowski, F, Lambert, J, Leleu, X, Macro, M, Orsini-Piocelle, F, Roussel, M, Stoppa, A M, van de Donk, N W C J, Wuillème, S, Broijl, A, Touzeau, C, Tiab, M, Marolleau, J P, Meuleman, N, Vekemans, M C, Westerman, M, Klein, S K, Levin, M D, Offner, F, Escoffre-Barbe, M, Eveillard, J R, Garidi, R, Ahmadi, T, Krevvata, M, Zhang, K, de Boer, C, Vara, S, Kampfenkel, T, Vanquickelberghe, V, Vermeulen, J, Avet-Loiseau, H & Sonneveld, P 2021, ' Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 10, pp. 1378-1390 . https://doi.org/10.1016/S1470-2045(21)00428-9
The Lancet. Oncology, Vol. 22, no. 10, p. 1378-1390 (2021)
Background: CASSIOPEIA part 1 showed superior depth of response and significantly improved progression-free survival with daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) as induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc1129b347cff7fbfcf632147289e27e
https://pure.eur.nl/en/publications/8f8a69b8-5b29-4b37-a68b-0449871cf60a
https://pure.eur.nl/en/publications/8f8a69b8-5b29-4b37-a68b-0449871cf60a
Autor:
Joseph R. Mace, Mourad Tiab, Philippe Moreau, Torben Plesner, Margaret Macro, Aurore Perrot, Katja Weisel, Noopur Raje, Michael O'Dwyer, Maia Trial Investigators, Shaji Kumar, Tahamtan Ahmadi, Clarissa M. Uhlar, Michel Attal, Ming Qi, Hang Quach, Thierry Facon, Hartmut Goldschmidt, Cyrille Hulin, Jianping Wang, Laurent Frenzel, Hareth Nahi, Robert Z. Orlowski, Rachel Kobos, Nizar J. Bahlis, Christopher P. Venner, Rian Van Rampelbergh, Christopher Chiu, Xavier Leleu, Supratik Basu, Saad Z. Usmani
Publikováno v:
Facon, T, Kumar, S, Plesner, T, Orlowski, R Z, Moreau, P, Bahlis, N, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O’Dwyer, M, Perrot, A, Venner, C P, Weisel, K, Mace, J R, Raje, N, Attal, M, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Ahmadi, T, Chiu, C, Wang, J, Rampelbergh, R V, Uhlar, C M, Kobos, R, Qi, M, Usmani, S Z, MAIA Trial Investigators & Abildgaard, N 2019, ' Daratumumab plus lenalidomide and dexamethasone for untreated Myeloma ', New England Journal of Medicine, vol. 380, no. 22, pp. 2104-2115 . https://doi.org/10.1056/NEJMoa1817249
BACKGROUND: Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would signi
Autor:
Denis Caillot, Shiyi Yang, Vincent H.J. van der Velden, Sonja Zweegman, Lionel Karlin, Margaret Macro, Niels W.C.J. van de Donk, Marie C. Béné, Fabio Rigat, Herve Avet Loiseau, Saskia K. Klein, Carla de Boer, Mark-David Levin, Jessica Vermeulen, Jérôme Lambert, Mohamad Mohty, Maria Krevvata, Tobias Kampfenkel, Aurore Perrot, Cyrille Hulin, Annemiek Broyl, Kon-Siong G. Jie, Veronique Vanquickelberghe, Pieter Sonneveld, Michel Delforge, Fritz Offner, Soraya Wuilleme, Jill Corre, Philippe Moreau, Bertrand Arnulf, Anne-Marie Stoppa
Publikováno v:
Blood. 138:82-82
Introduction: The 2-part phase 3 CASSIOPEIA study (NCT02541383) investigated the combination of DARA with VTd (D-VTd) in transplant-eligible NDMM pts. D-VTd induction/consolidation (ind/cons) led to increased rates of MRD negativity and prolonged pro
Autor:
Torben Plesner, Xavier Leleu, Supratik Basu, Noopur Raje, Joseph R. Mace, Saad Z. Usmani, Maria Delioukina, Hang Quach, Hartmut Goldschmidt, Huiling Pei, Shaji Kumar, Katja Weisel, Philippe Moreau, Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Laurent Frenzel, Mourad Tiab, Robert Z. Orlowski, Aurore Perrot, Cyrille Hulin, Michael O'Dwyer, Margaret Macro, Hareth Nahi, Brenda Tromp
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S1
Introduction In the primary analysis of MAIA, daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) reduced the risk of disease progression or death by 44% vs lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (pts) with ne
Autor:
Noopur Raje, Torben Plesner, Michael O'Dwyer, Rian Van Rampelbergh, Mourad Tiab, Clarissa M. Uhlar, Margaret Macro, Nizar J. Bahlis, Jianping Wang, Hartmut Goldschmidt, Brenda Tromp, Cyrille Hulin, Laurent Frenzel, Aurore Perrot, Hang Quach, Tahamtan Ahmadi, Shaji Kumar, Hareth Nahi, Jessica Vermeulen, Katja Weisel, Supratik Basu, Saad Z. Usmani, Philippe Moreau, Christopher P. Venner, Robert Z. Orlowski, Xavier Leleu, Joseph R. Mace, Thierry Facon, Maria Delioukina
Publikováno v:
Orlowski, R Z, Facon, T, Kumar, S K, Plesner, T, Moreau, P, Bahlis, N J, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M, Perrot, A, Venner, C P, Weisel, K, Mace, J R, Raje, N, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Ahmadi, T, Wang, J, Van Rampelbergh, R, Uhlar, C, Tromp, B, Delioukina, M, Vermeulen, J & Usmani, S Z 2021, ' MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM) ', Clinical Lymphoma, Myeloma & Leukemia, vol. 21, no. Suppl. 1, S252 . https://doi.org/10.1016/S2152-2650(21)01581-0
Context Daratumumab plus standard-of-care (SOC) showed superior efficacy vs SOC for patients with TIE-NDMM (phase 3 ALCYONE, MAIA, and CASSIOPEIA; primary analyses). In ALCYONE, after longer follow-up, adding daratumumab to bortezomib, melphalan, and
Autor:
Anne-Marie Stoppa, Aurore Perrot, Margaret Macro, Bruno Royer, Giovanni Palladini, Frank Bridoux, Laurent Frenzel, Murielle Roussel, Giampaolo Merlini, Véronique Dorvaux, Salomon Manier, David Lavergne, Antoine Huart, Bertrand Arnulf, Lionel Karlin, Pierre Morel, Arnaud Jaccard
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e40-e41
Autor:
David Beauvais, Karel Fostier, Laurent Frenzel, Hélène Demarquette, Eileen M Boyle, Aurore Perrot, Charles Zarnitsky, Xavier Leleu, Hervé Avet-Loiseau, Thomas Dejoie, Salomon Manier, Lionel Karlin, Schraen Susanna, Stéphanie Poulain, Christopher P. Wardell, Bruno Royer, Hélène Caillon, Marie-Odile Petillon, Thierry Facon, Charles Herbaux, Chretien Marie-Lorraine, Ifm investigators, Mohamad Mohty, Laure Vincent, Margaret Macro, Brian A Walker, Chantal Doyen, Philippe Moreau
Publikováno v:
British journal of haematology, Vol. 187, no. 3, p. 319-327 (2019)
Single agent daratumumab has shown clinical activity in relapsed, refractory multiple myeloma (RRMM). The Intergroupe Francophone du Myélome 2014-04 trial was designed to further investigate daratumumab in combination with dexamethasone in triple RR